Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors.
Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors.
复制标题
DOI：
10.1016/j.adro.2020.100639
复制
发表时间：
2021-05
影响因子：
2.3
通讯作者：
Spraker MB
中科院分区：
文献类型：
--
作者：
Duriseti S;Kavanaugh J;Goddu S;Price A;Knutson N;Reynoso F;Michalski J;Mutic S;Robinson C;Spraker MB
立体定向全身放射治疗(SBRT)已被证明对转移性和/或不能切除的癌症患者有临床疗效。考虑到治疗效果和附近有风险的器官的技术考虑，SBRT可能会限制在大型肿瘤或位于不利位置的肿瘤中使用SBRT。空间分割放射治疗(SFRT)可以解决这一限制，因为这种技术可以向肿瘤靶区内离散的亚体积顶点提供高剂量辐射，同时将靶区的其余部分限制在更安全的低剂量范围内。事实上，SFRT，如GRID，已经被用于治疗大型肿瘤，据报道，它具有显著的肿瘤反应和最小的副作用。格来特是一种现代的SFRT方法，它与弧形治疗相结合，可能允许安全、高质量的SBRT治疗大型和/或深部肿瘤。在这里，我们报告了11例患者12个肿瘤靶点的剂量学和质量保证可行性研究的结果，每个≥轴向10厘米。先前的计算机断层扫描被用来生成容量调制弧形治疗格子SBRT计划，然后在临床可用的LINAC上进行交付。质量保证测试包括外部射野成像设备和电离室分析。所有生成的计划都符合标准的SBRT剂量限制，例如来自美国物理学家协会医学任务组101的限制。此外，我们提供了一种循序渐进的方法，使用商业上可用的治疗技术来生成和交付晶格SBRT计划。格列格SBRT目前正在对需要大肿瘤姑息治疗的转移性癌症患者进行前瞻性试验(NCT04553471，NCT04133415)。
Stereotactic body radiation therapy (SBRT) has demonstrated clinical benefits for patients with metastatic and/or unresectable cancer. Technical considerations of treatment delivery and nearby organs at risk can limit the use of SBRT in large tumors or those in unfavorable locations. Spatially fractionated radiation therapy (SFRT) may address this limitation because this technique can deliver high-dose radiation to discrete subvolume vertices inside a tumor target while restricting the remainder of the target to a safer lower dose. Indeed, SFRT, such as GRID, has been used to treat large tumors with reported dramatic tumor response and minimal side effects. Lattice is a modern approach to SFRT delivered with arc-based therapy, which may allow for safe, high-quality SBRT for large and/or deep tumors. Herein, we report the results of a dosimetry and quality assurance feasibility study of Lattice SBRT in 11 patients with 12 tumor targets, each ≥10 cm in an axial dimension. Prior computed tomography simulation scans were used to generate volumetric modulated arc therapy Lattice SBRT plans that were then delivered on clinically available Linacs. Quality assurance testing included external portal imaging device and ion chamber analyses. All generated plans met the standard SBRT dose constraints, such as those from the American Association of Physicists in Medicine Task Group 101. Additionally, we provide a step-by-step approach to generate and deliver Lattice SBRT plans using commercially available treatment technology. Lattice SBRT is currently being tested in a prospective trial for patients with metastatic cancer who need palliation of large tumors (NCT04553471, NCT04133415).
登录
查看更多内容
影响因子：
10.3
作者：
Hartsell, WF;Scott, CB;DeSilvio, M
通讯作者：
DeSilvio, M
影响因子：
3.8
作者：
Miften, Moyed;Olch, Arthur;Low, Daniel A.
通讯作者：
Low, Daniel A.
影响因子：
2.1
作者：
Sheikh, Khadija;Hrinivich, William T.;Meyer, Jeffrey
通讯作者：
Meyer, Jeffrey
DOI：
10.1016/j.ijrobp.2013.08.020
发表时间：
2013-12-01
影响因子：
7
作者：
Allibhai, Zishan;Taremi, Mojgan;Cho, B. C. John
通讯作者：
Cho, B. C. John
影响因子：
20.4
作者：
Shiue, Kevin;Cerra-Franco, Alberto;Lautenschlaeger, Tim
通讯作者：
Lautenschlaeger, Tim